Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) reports the results of the company's Annual General Meeting (AGM) held on May 3, 2012. The filing confirms that all shareholder resolutions were passed. The document serves as a notification of corporate governance outcomes rather than a financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on voting results and share capital statistics.
- Issued Share Capital (excluding Treasury Shares): 5,046,404,827 shares.
- Total Votes Cast and Withheld: 76.91% of issued share capital.
- Total Shareholder Population: 147,408.
Material Changes Versus Prior Period
Comparisons with the 2011 AGM indicate the following changes:
- Share Capital: Issued share capital decreased from 5,163,907,153 in 2011 to 5,046,404,827 in 2012.
- Shareholder Participation: The percentage of issued share capital represented by votes cast and withheld increased from 74.72% in 2011 to 76.91% in 2012.
- Shareholder Population: The total number of shareholders decreased from 155,990 in 2011 to 147,408 in 2012.
- Board Composition: James Murdoch did not stand for re-election and stepped down from the Board effective noon on May 3, 2012.
Guidance, Outlook, and Governance Results
The filing details the successful passage of 26 resolutions, including the adoption of financial statements, director re-elections, and auditor appointments. Key voting outcomes include:
- Remuneration Report: Approved with 95.70% of votes cast in favor.
- Director Re-elections: All directors standing for re-election received over 96% support, with several receiving over 99% approval.
- Share Buyback Authority: Authority to purchase own shares was approved with 99.55% support.
- Political Donations: Authority to make political donations was approved with 98.23% support.
The filing contains no management commentary on future financial guidance, risks, or contingencies.
Investor Verification Checklist
- Verify the reduction in issued share capital to confirm the extent of share buybacks or treasury share adjustments since 2011.
- Confirm the departure of James Murdoch from the Board and any subsequent changes to board committee structures.
- Review the full Remuneration Report referenced in Resolution 2 to understand the specific compensation packages approved by 95.70% of voters.
- Check the company website (www.gsk.com) for the detailed financial statements adopted in Resolution 1, as this filing does not contain financial data.